Shell Technique for Implant Site Development

October 3, 2026 updated by: Azza Mohamed Nasr, Cairo University

Clinical and Radiographic Efficacy of Horizontal Alveolar Ridge Augmentation Using Shell Technique Via Autogenous Versus Xenogenic Bone Graft for Implant Site Development

The goal of this clinical trial is to learn if shell technique is useful for implant placement site preparation in adults. The main questions it aims to answer are:

Does using xenograft in this technique can reduce the amount of bone harvested from intra oral sites and reduce postoperative complications while offering enough bone to support endosseous implants with long term success?

Researchers will compare autogenous bone blocks to xenograft bone blocks in the shell technique ridge augmentation.

Participants will undergo ridge augmentation surgery, then have implants placed in the augmented area, then receive implant supported restorations afterwards.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients who are attending NGU clinics seeking rehabilitation of upper inter-bicuspid edentulous ridges.
  2. Edentulous ridges with adequate bone height, but inadequate bone width.
  3. Patients' ages are between 20-60 years.
  4. Medically free patients, who are nonsmokers.
  5. Good oral hygiene.

Exclusion Criteria:

  1. Patients who have undergone previous bone augmentation in the upper interbicuspid edentulous ridges.
  2. Edentulous ridges with inadequate bone height.
  3. Patients who have systemic diseases or who are taking drugs affecting quality of bone.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Study group (Xenograft)

group will receive xenograft shell bone fixed to the edentulous ridge with a screw keeping it at a distance from the ridge and particulate xenograft to fill the gap.

Active Comparator: Control group (Autograft)

group will receive autogenous bone shell harvested from the retromolar area fixed to the edentulous area with screws keeping it at a distance from the ridge and particulate bone to fill the gap formed of particulate autograft.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ridge width gain
Time Frame: 6 months

increase in the alveolar ridge width in millimeters

6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
implant survival
Time Frame: 12 months
12 months
Facial keratinized mucosal width
Time Frame: 6 months
6 months
Facial mucosal thickness
Time Frame: 6 months

facial mucosa thickness via transmucosal bone sounding

6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

September 30, 2026

First Submitted That Met QC Criteria

September 30, 2026

First Posted (Actual)

October 5, 2026

Study Record Updates

Last Update Posted (Actual)

October 7, 2026

Last Update Submitted That Met QC Criteria

October 3, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NGU 7.5

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.